Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;33(9):900-2.
doi: 10.1038/nbt.3322.

Availability and payer coverage of BRCA1/2 tests and gene panels

Elizabeth Clain  1 , Julia R Trosman  2   3 , Michael P Douglas  3 , Christine B Weldon  2   3 , Kathryn A Phillips  3   4
Affiliations

Availability and payer coverage of BRCA1/2 tests and gene panels

Elizabeth Clain et al. Nat Biotechnol. 2015 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details are available in the online version of the paper (doi:10.1038/nbt.3322).

Figures

Figure 1
Figure 1
Pricing for BRCA1/2-only and panel tests. Error bars represent the minimum and maximum values, the boxes show the 25th percentile to 75th percentile and the middle horizontal line shows median value. Two-gene test prices ranged from $500 to $2,895, with a mean price of $1,711 versus $4,040 for Myriad’s standard offering, Integrated BRACAnalysis. Pricing for panels including the BRCA1/2 genes ranged from $1,500 to $6,749 with a mean price of $3,357. Illumina’s TruGenome Predisposition Screen (BRCA gene analysis in a panel of 1,600 genes, $9,500) was excluded as an outlier.
See this image and copyright information in PMC

References

    1. Curnutte MA, Frumovitz KL, Bollinger JM, McGuire AL, Kaufman DJ. Nat Biotechnol. 2014;32:980–982. - PMC - PubMed
    1. Ratner M. Nat Biotechnol. 2013;31:663–665. - PubMed
    1. Weldon CB, Trosman JR, Gradishar WJ, Benson AB, III, Schink JC. J Oncol Pract. 2012;8:e24–31. - PMC - PubMed
    1. Trosman JR, Van Bebber SL, Phillips KA. J Oncol Pract. 2011;7:18s–24s. - PMC - PubMed
    1. Daly M, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic/Familial High-Risk Assessment: Breast and Ovarian (version 2.2105) 2015 http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed July 19, 2015.

Publication types

MeSH terms